Evotec SE (EVT.DE)
| Previous close | 13.21 |
| Open | 13.17 |
| Bid | 13.33 x 105300 |
| Ask | 13.34 x 169300 |
| Day's range | 12.98 - 13.45 |
| 52-week range | 12.61 - 24.44 |
| Volume | |
| Avg. volume | 736,768 |
| Market cap | 2.383B |
| Beta (5Y monthly) | 1.11 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- PR Newswire
EVOTEC AND VARIANT BIO ENTER STRATEGIC PARTNERSHIP TO DISCOVER AND DEVELOP FIBROSIS TREATMENTS
Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) and Variant Bio, Inc. today announced a collaboration agreement to identify a best-in-class treatment for diseases caused by fibrosis.
- GlobeNewswire
Dewpoint Therapeutics Enters Strategic Partnership with Evotec to Accelerate Oncology Pipeline
PARTNERSHIP TO ACCELERATE DEWPOINT’S LEADING ONCOLOGY PIPELINE PROGRAMS TO INVESTIGATIONAL NEW DRUG APPLICATIONS COLLABORATION LEVERAGES EVOTEC’S FULLY INTEGRATED, CLINICAL-ENABLING INDIGO CAPABILITY PLATFORMAGREEMENT IS BASED ON A RISK-SHARING ARRANGEMENT FOLLOWED BY MILESTONE AND ROYALTY PAYMENTS TO EVOTEC BASED ON SUCCESS OF OVERALL PROGRAMS HAMBURG, Germany and BOSTON, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) an
- GlobeNewswire
Successful Results Using Sernova’s Cell Pouch System™ with Evotec’s iPSC-Derived Islet-like Clusters for Type 1 Diabetes Presented at the 4th IPITA / HSCI / JDRF Summit
Evotec’s scalable GMP manufacturing process has been designed to produce induced pluripotent stem cell (iPSC)-derived islet-like clusters (ILCs) with high insulin-producing beta cell content as well as glucagon and somatostatin (produced by alpha cells and delta cells, respectively), similar to human isletsThe ILCs are cryopreserved during manufacturing, enabling storage of mass volumes and cost efficient on-demand worldwide delivery as requiredResults from a type 1 diabetes (T1D) preclinical mo
